Stock Price Prediction

ATNM stock has a bullish outlook with a price target of $5.75, representing a 307.8% upside from its current price of $1.41. Analysts are optimistic due to its strong pipeline in radiopharmaceuticals, particularly Iomab-B, despite recent regulatory setbacks. The stock's low valuation and potential strategic partnerships further support the bullish sentiment.

ATNM stock is currently trading at $2.05, significantly down from its recent highs. The bearish view stems from the FDA's rejection of its Phase III SIERRA trial for Iomab-B, requiring additional trials, which delays commercialization and increases costs. This regulatory setback has eroded investor confidence, leading to a sharp decline in the stock price.